Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: An Observational Postauthorisation Study
Phase of Trial: Phase IV
Latest Information Update: 22 Mar 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Macular degeneration
- Focus Adverse reactions
- Sponsors Bayer
- 17 Mar 2017 Status changed from active, no longer recruiting to completed.
- 29 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Jan 2017.
- 06 Oct 2016 Status changed from recruiting to active, no longer recruiting.